GATEWAY 2026
Threehorizons.
One company,
three doors.
Your bridge between the world and Japan's pharmaceutical & health industry.
7+
COUNTRIES
9+
PARTNERS
2023
FOUNDED
3
DOORS
Care Link
Specialty Pharma × Last Mile
Delivering directly to patients
Last-mile delivery of specialty pharmaceuticals from pharmacies to patient homes. End-to-end cold chain management, adherence monitoring, and PSP integration.
Global Bridge
Import × Export
A two-way bridge between Japan and the world
Japan market entry for overseas pharma and raw materials. Global expansion for Japanese OTC and supplements. Regulatory to logistics, end-to-end.
garden
Supplement Development
From idea to product
Supplement and health food planning to manufacturing. OEM/ODM, raw material sourcing, and branding support.
Latest Insights
Healthcare insights shared by CEO Masaya Yamamoto on NewsPicks
ロンジェビティ産業 ― 「日本の長寿」は集団知か個人商品か
The buzz around a ¥4.1 million-per-month longevity resort on Awaji Island signals that 'Japanese longevity' itself is becoming a premium product—but I think we should be careful about what that framing obscures. Japan's healthy life expectancy was not purchased by individuals through intensive personal programs; it was built through population-wide measures: widespread salt reduction and blood-pressure management, workplace and municipal health screenings, and the accessibility of care under universal insurance. A resort offering dense, individualized intervention is, by design, moving in precisely the opposite direction from what actually produced Japanese longevity. If the offering is marketed under the banner of 'Japanese know-how,' it's worth being explicit about where that lineage genuinely applies and where it ends. The article asks what people seek beyond mere longevity, and here Japan holds no model answer—it is a country already living with the consequences: social isolation among the elderly, and the lived reality that preserving physical function to age 100 means little if roles and connections have been lost along the way. Whether longevity is measured by cellular and biomarker youth alone, or treated as the design of a life that remains worth living over the long run, is a question Japan is compelled to confront firsthand—and that, I believe, is the genuinely distinctive perspective Japan can bring to this conversation.
小林製薬の非公開化検討 ― 問われるヘルスケア企業のガバナンス設計
The discussion around Kobayashi Pharmaceutical's potential privatization is often framed as corporate restructuring in the wake of the red yeast rice supplement scandal, but it should also be read as a structural issue for the healthcare industry at large. In Japan, the market for OTC drugs and functional foods has expanded while the boundary between the two categories remained blurred, leaving safety management systems and adverse-event reporting mechanisms inadequately developed across the industry, regardless of company size. This incident has exposed those weaknesses, and the question of going public or private should not distract from the more fundamental challenge of redesigning product-safety governance. The logic that privatization—by shielding management from short-term shareholder pressure—could enable deeper structural reform is understandable. However, transparency and disclosure are the bedrock of trust for any healthcare company, and if privatization erodes them, stakeholder risk simply shifts to a different form. The core question is how to rebuild trust with consumers, healthcare professionals, and regulators—and under which governance structure that rebuilding should be designed.
精密栄養学の成長市場 ― 技術・制度・格差の三課題
The limitations of a "one-size-fits-all" diet have long been debated in nutritional science, and given individual variation in gut microbiota, genetic polymorphisms, and metabolic responses, it is time to seriously reconsider how crude population-averaged dietary guidelines have always been. That said, reading a $66.9 billion market figure as straightforward validation of precision nutrition may be premature. Even as the costs of wearables and comprehensive omics analysis fall, the technology risks floating in mid-air unless "translators" capable of interpreting data within each person's real-life context can keep pace—meaning that the benefits of individualization will only reach daily life once clinical dietitians, registered nutritionists, and primary care physicians are equipped to work with precision nutrition insights. In Japan, the infrastructure for incorporating dietary intervention evidence into insurance-covered care remains fragile, creating a risk that the out-of-pocket market races ahead on its own. The question of who can actually access precision nutrition must be answered not only as a market-sizing discussion but as a matter of institutional design—and that moment has already arrived.